HALO vs ACAD Stock Comparison: AI Score, Valuation, Performance and Upside
HALO operates a capital-light drug delivery technology licensing business with growing, high-margin royalty streams from partner drugs, while ACAD is a direct drug developer with two approved CNS drugs facing commercial challenges and ongoing pipeline investment. Both are mid-cap biotechs but with fundamentally different business models and risk profiles.
HALO vs ACAD compares a capital-light drug delivery technology licensor with growing royalty streams against a direct CNS drug developer with approved products navigating commercial execution challenges.
HALO holds the edge across 4 of 5 key metrics in this comparison. HALO leads on both 1-year return (+46.65%) and forward P/E quality (10.48x vs 31.27x for ACAD), a relatively favorable combination of momentum and valuation. HALO leads on both revenue growth (47.70%) and operating margin (59.80%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ACAD (+22.17%) than for HALO (-8.62%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a capital-light, high-margin drug delivery technology royalty business
- Value the diversification from multiple approved partner drugs generating Halozyme royalties
- Appreciate the lower clinical risk profile versus direct drug development
- Want exposure to a CNS drug developer with two approved commercial products
- Believe Daybue adoption in Rett syndrome will improve as physician and patient experience grows
- See value in Acadia's pipeline potential beyond its current approved drugs
| Metric | HALO | ACAD |
|---|---|---|
| AI scorei | 55.1 | 25.8 |
| AI ranki | #276 | #2715 |
| Latest closei | $112.45 | $27.29 |
| 1M returni | +4.49% | -9.67% |
| 6M returni | +77.28% | +31.58% |
| 1Y returni | +46.65% | +10.22% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | HALO | ACAD |
|---|---|---|
| 1Y ago | $14.45K (+44.5%) started 2025-09-19 | $11.02K (+10.2%) started 2025-09-18 |
| 5Y ago | $27.27K (+172.7%) started 2021-09-20 | $16.33K (+63.3%) started 2021-09-20 |
| 10Y ago | $93.09K (+830.9%) started 2016-09-19 | $7.84K (-21.6%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | HALO | ACAD |
|---|---|---|
| Market capi | $12.37B | $4.8B |
| Trailing P/Ei | 31.95 | 12.48 |
| Forward P/Ei | 10.48 | 31.27 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 8.52 | 3.44 |
| Analyst targeti | $99.56 | $34.00 |
| Target upsidei | -8.62% | +22.17% |
| Metric | HALO | ACAD |
|---|---|---|
| Revenue growthi | 47.70% | 16.40% |
| Earnings growthi | 42.90% | 13.30% |
| EPS growthi | +42.90% | +13.30% |
| FCF margini | +20.27% | +6.03% |
| Operating margini | 59.80% | 12.29% |
| Profit margini | 24.86% | 33.42% |
| ROIC proxyi | 173.67% | 35.74% |
| Return on equityi | 173.67% | 35.74% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.85 | 0.86 |
| Debt/equityi | 1517.69 | 5.65 |
| Current ratioi | 2.71 | 3.39 |
| Quick ratioi | 1.99 | 3.11 |
Over the past year, HALO and ACAD have moved weakly in the same direction (correlation of 0.27), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | HALO | ACAD |
|---|---|---|---|
| 1Y | Growthi | +44.52% | +10.22% |
| CAGRi | +44.69% | +10.23% | |
| Volatilityi | 37.13% | 37.54% | |
| Sharpe ratioi | 1.06 | 0.33 | |
| Sortino ratioi | 1.85 | 0.48 | |
| Max drawdowni | 24.13% | 27.58% | |
| Current drawdowni | 0.00% | 10.73% | |
| Avg drawdowni | 11.01% | 12.39% | |
| Ulcer Indexi | 13.06% | 14.91% | |
| Max daily dropi | 9.01% | 9.92% | |
| Max wkly dropi | 13.36% | 14.34% | |
| 5Y | Growthi | +172.74% | +63.32% |
| CAGRi | +22.25% | +10.32% | |
| Volatilityi | 40.43% | 55.07% | |
| Sharpe ratioi | 0.59 | 0.37 | |
| Sortino ratioi | 0.87 | 0.56 | |
| Max drawdowni | 49.06% | 57.87% | |
| Current drawdowni | 0.00% | 18.46% | |
| Avg drawdowni | 17.62% | 31.71% | |
| Ulcer Indexi | 21.76% | 35.10% | |
| Max daily dropi | 24.56% | 33.32% | |
| Max wkly dropi | 31.69% | 24.96% | |
| 10Y | Growthi | +830.88% | -21.63% |
| CAGRi | +25.00% | -2.41% | |
| Volatilityi | 42.54% | 61.70% | |
| Sharpe ratioi | 0.63 | 0.20 | |
| Sortino ratioi | 0.95 | 0.29 | |
| Max drawdowni | 49.06% | 77.18% | |
| Current drawdowni | 0.00% | 52.12% | |
| Avg drawdowni | 16.58% | 46.93% | |
| Ulcer Indexi | 20.12% | 51.98% | |
| Max daily dropi | 24.56% | 45.35% | |
| Max wkly dropi | 31.69% | 46.70% |
| Category | HALO | ACAD |
|---|---|---|
| Company | Halozyme Therapeutics, Inc. | Acadia Pharmaceuticals Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Halozyme develops and licenses its ENHANZE drug delivery technology — using recombinant human hyaluronidase (rHuPH20) — enabling large-molecule drugs to be delivered subcutaneously (under the skin) instead of intravenously, offering convenience benefits for patients with existing biologics. | Acadia Pharmaceuticals develops drugs for central nervous system (CNS) conditions, with approved products including Nuplazid (pimavanserin) for Parkinson's disease psychosis and Daybue (trofinetide) for Rett syndrome, a rare pediatric neurological disorder. |
| Investor focus | Investors track Halozyme's ENHANZE royalty revenue growth as partner drugs launch subcutaneous formulations, the number of approved and pipeline ENHANZE-partnered drugs, and Halozyme's capital return program. | Investors track Daybue's Rett syndrome patient uptake and revenue growth, Nuplazid's commercial trajectory, and Acadia's pipeline including additional CNS indications. |
- Capital-light royalty business model generates high-margin, recurring revenue from partner drug sales without Halozyme needing to own or market drugs directly
- ENHANZE has been adopted by major pharma companies including Roche, Johnson & Johnson, AstraZeneca, and others
- Growing royalty streams from multiple approved partner drugs provide revenue diversification
- Nuplazid is the only FDA-approved drug specifically for Parkinson's disease psychosis, providing a defined and durable niche
- Daybue is the first-ever approved treatment for Rett syndrome, establishing Acadia in the rare neurological disease space
- CNS disease focus provides potential for additional orphan designations and pipeline leverage
- Royalty revenue is dependent on partner drug commercial success — if a partnered drug fails or underperforms, royalty streams disappoint
- Technology licensing model provides less upside than owning drug franchises directly
- Competition from other subcutaneous delivery technologies could reduce future partner uptake
- Daybue tolerability concerns (particularly gastrointestinal side effects) have limited patient uptake versus initial expectations
- Nuplazid has faced persistent safety scrutiny and limited prescription growth due to the challenging Parkinson's disease patient management context
- High operating expenses relative to revenue keep Acadia loss-making
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.